Michailidou, Despina
Khaki, Ali Raza
Morelli, Maria Pia
Diamantopoulos, Leonidas
Singh, Namrata
Grivas, Petros
Funding for this research was provided by:
Pfizer US Pharmaceuticals Group grant (53857367)
National Cancer Institute , United states (T32CA009515)
American Heart Association (19IPLOI34760622)
Article History
Received: 27 December 2020
Accepted: 29 March 2021
First Online: 27 April 2021
Competing interests
: Dr. D Michailidou has no disclosures. Dr. AR Khaki: owned stock from Merck and Sanofi within the last 3 years. Dr. MP Morelli has not disclosures. Dr. L Diamantopoulos has no disclosures. Dr. N Singh has no disclosures. Dr. P Grivas (all unrelated in the last 3 years): Consulting: AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Dyania Health, Driver; EMD Serono; Exelixis; Foundation Medicine; Genentech/Roche; Genzyme; GlaxoSmithKline; Heron Therapeutics; Immunomedics, Infinity Pharmaceuticals; Janssen; Merck; Mirati Therapeutics; Pfizer; Seattle Genetics; QED Therapeutics. Research Funding to Institution: Merck; Pfizer, Clovis Oncology, Bavarian Nordic, Immunomedics, Debiopharm, Bristol-Myers Squibb, QED Therapeutics, GlaxoSmithKline, Mirati Therapeutics, Kure It Cancer Research.